Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.50 |
| ▸ | CTSA | P10619 | 9/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1389612 | 1.00 | GPBAR1 (0.50) | GPBAR1CTSALRRK2ALDH1A1GAA | |
| SCHEMBL361789 | 1.00 | GPBAR1 (0.50) | GPBAR1CTSALRRK2ALDH1A1GAA | |
| SCHEMBL10240885 | 0.93 | GPBAR1 (0.54) | GPBAR1CTSA | |
| SCHEMBL363140 | 0.93 | GPBAR1 (0.54) | GPBAR1CTSA | |
| SCHEMBL363141 | 0.93 | GPBAR1 (0.54) | GPBAR1CTSA | |
| SCHEMBL10240923 | 0.93 | GPBAR1 (0.58) | GPBAR1CTSALRRK2CSNK2A2CSNK2B | |
| SCHEMBL364300 | 0.93 | GPBAR1 (0.58) | GPBAR1CTSALRRK2CSNK2A2CSNK2B | |
| SCHEMBL364299 | 0.93 | GPBAR1 (0.58) | GPBAR1CTSALRRK2CSNK2A2CSNK2B | |
| SCHEMBL369007 | 0.91 | GPBAR1 (0.55) | GPBAR1CTSALRRK2ALDH1A1GAA | |
| SCHEMBL364283 | 0.91 | GPBAR1 (0.55) | GPBAR1CTSALRRK2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | GPBAR1 1/4885CTSA 3225/4885LRRK2 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.